Biogen (BIIB) advanced nearly 4% after JPMorgan upgraded the stock to overweight from neutral. Several clinical trial readouts expected in 2027 were identified as potential catalysts.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
